NCT01730586View on ClinicalTrials.gov

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Colorectal CancerCancer of Gastrointestinal Tract
Interventions
DRUG

Abraxane

220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT01730586 - Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas | Biotech Hunter | Biotech Hunter